✨ Medicine Approvals and Drug Prohibition




NEW ZEALAND GAZETTE

No. 161

4476

Product:
Zyprexa Zydis

Active Ingredient:
Olanzapine 10mg

Dosage Form:
Wafer

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England

Product:
Zyprexa Zydis

Active Ingredient:
Olanzapine 15mg

Dosage Form:
Wafer

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England

Product:
Zyprexa Zydis

Active Ingredient:
Olanzapine 20mg

Dosage Form:
Wafer

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England

Product:
Zyprexa Zydis

Active Ingredient:
Olanzapine 5mg

Dosage Form:
Wafer

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England

Product:
Zyprexa

Active Ingredient:
Olanzapine 10mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturers:
Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico

Product:
Zyprexa

Active Ingredient:
Olanzapine 2.5mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturers:
Eli Lilly and Company Limited, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico

Product:
Zyprexa

Active Ingredient:
Olanzapine 5mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturers:
Eli Lilly and Company Limited, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico

Product:
Zyprexa

Active Ingredient:
Olanzapine 7.5mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited

Manufacturers:
Eli Lilly and Company Limited, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico

Dated this 24th day of November 2003.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).

go7813

Misuse of Drugs Act 1975

Prohibition of the Prescribing of Controlled Drugs

Pursuant to section 23 (1) (a) of the Misuse of Drugs Act 1975, I, Annette King, Minister of Health, on the recommendation of the Medical Council of New Zealand,

hereby prohibit the prescribing of Class B and Class C controlled drugs by

Dr Malcolm Paul Lay, medical practitioner of Oamaru.

Dated at Wellington this 24th day of November 2003.

ANNETTE KING, Minister of Health.

go7876



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2003, No 161


Gazette.govt.nz PDF NZ Gazette 2003, No 161





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of Changed Medicines (continued from previous page)

πŸ₯ Health & Social Welfare
24 November 2003
Medicines Act 1981, Changed medicines, Zyprexa Zydis, Zyprexa, Olanzapine
  • DON MATHESON, Deputy Director-General, Public Health

πŸ₯ Prohibition of Prescribing Controlled Drugs

πŸ₯ Health & Social Welfare
24 November 2003
Misuse of Drugs Act 1975, Controlled drugs, Prescribing prohibition, Medical practitioner
  • Malcolm Paul Lay (Doctor), Prohibited from prescribing Class B and C controlled drugs

  • ANNETTE KING, Minister of Health